| scholarly article | Q13442814 |
| P2093 | author name string | Keykavous Parang | |
| John Marshall | |||
| Rakesh Tiwari | |||
| Dennis J Goebel | |||
| Shaban Darwish | |||
| P2860 | cites work | Syntenin is overexpressed and promotes cell migration in metastatic human breast and gastric cancer cell lines | Q24298538 |
| Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein | Q24654803 | ||
| A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage | Q27677328 | ||
| Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ | Q27732927 | ||
| PDZ domains: folding and binding | Q28235804 | ||
| CRIPT, a novel postsynaptic protein that binds to the third PDZ domain of PSD-95/SAP90 | Q28270363 | ||
| Origin of PDZ (DHR, GLGF) domains | Q28284240 | ||
| Inhibition of N-Methyl-D-aspartate-induced Retinal Neuronal Death by Polyarginine Peptides Is Linked to the Attenuation of Stress-induced Hyperpolarization of the Inner Mitochondrial Membrane Potential | Q28388814 | ||
| Impairment of TrkB-PSD-95 signaling in Angelman syndrome | Q28486135 | ||
| The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo | Q35020321 | ||
| Part I: parkin-associated proteins and Parkinson's disease. | Q35157619 | ||
| Ligand binding by PDZ domains. | Q38016834 | ||
| Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions | Q44193907 | ||
| The expanding role of PSD-95: a new link to addiction | Q45149180 | ||
| Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction | Q46351668 | ||
| Thermodynamic profiling of conformationally constrained cyclic ligands for the PDZ domain | Q47987566 | ||
| Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. | Q48342501 | ||
| Emerging mechanisms of disrupted cellular signaling in brain ischemia | Q48819832 | ||
| P433 | issue | 31 | |
| P304 | page(s) | 3053-3056 | |
| P577 | publication date | 2017-06-23 | |
| P1433 | published in | Tetrahedron Letters | Q903432 |
| P1476 | title | Efficient synthesis of CN2097 using in situ activation of sulfhydryl group | |
| P478 | volume | 58 |
Search more.